Molecular Characterisation of Appendiceal Cancer
Characterisation of Appendiceal Cancer by Genomic and Transcriptomic Analysis and Correlation With Clinical Outcomes
The Christie NHS Foundation Trust
100 participants
Feb 4, 2024
OBSERVATIONAL
Conditions
Summary
Patients ≥ 18 years old who have been diagnosed with appendiceal cancer with peritoneal metastases, have had cytoreductive surgery, have availability of archival tumour tissue and have consented to our institutional biobank program or have a waiver of consent for deceased patients who have not had the opportunity to provide biobank consent (requested at the time of ethics review). Descriptive analysis of the proportion of genetic mutations identified in appendiceal cancers. This is given by the percentage of pathogenic mutations in the peritoneal metastasis compared to the primary tumour.
Eligibility
Inclusion Criteria4
- Participants are eligible to be included in the study only if all of the following criteria apply:
- Patients ≥ 18 years old who have been diagnosed with appendiceal cancer with peritoneal metastases,
- have had cytoreductive surgery
- have availability of archival tumour tissue
Exclusion Criteria1
- None
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
Acquisition of archival Formalin Fixed Paraffin Embedded (FFPE) human tissue from appendix cancer primary tumour and peritoneal metastases, which are stored in NHS pathology - taken from standard care biopsies.
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT05364788